Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Review

Circulating epigenetic biomarkers in melanoma

Authors: Yu Xin, Zheng Li, Matthew T.V. Chan, William Ka Kei Wu

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Recent researches have shed new light on the importance of epigenetic alterations, including promoter hypermethylation and microRNA dysregulation, in the initiation and progression of melanoma. The clinical utilization of circulating epigenetic markers in melanoma has also been investigated. In this review, we explored the literature and summarized the latest progress in the discovery of circulating epigenetic markers, namely methylated DNA and microRNAs, for non-invasive diagnosis of melanoma, as well as their measurability and predictability. We also discussed the utility of these epigenetic markers as novel prognostic and predictive markers and their association with melanoma clinical phenotypes, including recurrence and patients’ survival. Large-cohort validations are warranted to maximize the clinical utilization of these markers.
Literature
1.
Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic mir-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40:841–9.CrossRefPubMedPubMedCentral
2.
Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral
3.
Sari Aslani F, Geramizadeh B, Dehghanian AR. Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa. Med J Islam Republic Iran. 2015;29:203.
4.
Walesch SK, Richter AM, Helmbold P, Dammann RH. Claudin11 promoter hypermethylation is frequent in malignant melanoma of the skin, but uncommon in nevus cell nevi. Cancer. 2015;7:1233–43.CrossRef
5.
Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, et al. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a surveillance, epidemiology and end results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. Br J Haematol. 2015;171:84–90.CrossRefPubMedPubMedCentral
6.
7.
Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30:355–61.CrossRefPubMed
8.
Brenner H. Mortality from malignant melanoma in an era of nationwide skin cancer screening. Dtsch Arztebl Int. 2015;112:627–8.PubMedPubMedCentral
9.
Merrill RM. Risk-adjusted melanoma skin cancer incidence rates in whites (United States). Melanoma Res. 2011;21:535–40.CrossRefPubMed
10.
Majewski W, Stanienda K, Wicherska K, Ulczok R, Wydmanski J. Treatment outcome and prognostic factors for malignant skin melanoma treated with radical surgery. Asian Pac J Cancer Prev. 2015;16:5709–14.CrossRefPubMed
11.
Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, Lopez MC, Innos K, Minicozzi P, Borgognoni L, Pierannunzio D, Eisemann N: Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015
12.
Coups EJ, Manne SL, Stapleton JL, Tatum KL, Goydos JS: Skin self-examination behaviors among individuals diagnosed with melanoma. Melanoma research 2015
13.
14.
15.
Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342:200–12.CrossRefPubMed
16.
17.
Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, et al. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene. 2010;29:6390–401.CrossRefPubMedPubMedCentral
18.
Niles LP, Pan Y, Kang S, Lacoul A. Melatonin induces histone hyperacetylation in the rat brain. Neurosci Lett. 2013;541:49–53.CrossRefPubMed
19.
Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56.CrossRefPubMedPubMedCentral
20.
Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011;585:2467–76.CrossRefPubMed
21.
Howell Jr PM, Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control. 2009;16:200–18.PubMed
22.
Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res. 2012;22:101–13.CrossRefPubMed
23.
Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012;3:1011–25.CrossRefPubMedPubMedCentral
24.
Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, et al. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol. 2015;28:884–94.CrossRefPubMed
25.
Voso MT, Lo-Coco F, Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol. 2015;27:532–9.CrossRefPubMed
26.
Duvic M. Histone deacetylase inhibitors for cutaneous T-cell lymphoma. Dermatol Clin. 2015;33:757–64.CrossRefPubMed
27.
Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czec. 2014;158:161–9.
28.
Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013;133:1278–85.CrossRefPubMed
29.
Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012;132:1689–97.CrossRefPubMedPubMedCentral
30.
Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342:170–7.CrossRefPubMed
31.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.CrossRefPubMed
32.
Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One. 2011;6:e27840.CrossRefPubMedPubMedCentral
33.
Tsumagari K, Baribault C, Terragni J, Chandra S, Renshaw C, Sun Z, et al. DNA methylation and differentiation: HOX genes in muscle cells. Epigenetics Chromatin. 2013;6:25.CrossRefPubMedPubMedCentral
34.
Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. Mir-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer. 2011;10:124.CrossRefPubMedPubMedCentral
35.
Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012;33:1629–38.CrossRefPubMed
36.
Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res. 2011;67:1–23.PubMed
37.
Lauss M, Ringner M, Karlsson A, Harbst K, Busch C, Geisler J, et al. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics. 2015;8:73.CrossRefPubMedPubMedCentral
38.
Liu Y, Dong Z, Liang J, Guo Y, Guo X, Shen S, Kuang G, Guo W: Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015
39.
Otsubo T, Hagiwara T, Tamura-Nakano M, Sezaki T, Miyake O, Hinohara C, et al. Aberrant DNA hypermethylation reduces the expression of the desmosome-related molecule periplakin in esophageal squamous cell carcinoma. Cancer Med. 2015;4:415–25.CrossRefPubMedPubMedCentral
40.
Nazarian R, Jazirehi AR. TFPI2 methylation can serve as an epigenetic biomarker of metastatic melanoma. Epigenomics. 2013;5:252–3.PubMed
41.
Perez-Ramirez C, Canadas-Garre M, Molina MA, Faus-Dader MJ, Calleja-Hernandez MA. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16:1843–62.CrossRefPubMed
42.
Zheng J, Dai Y, Yang Z, Yang L, Peng Z, Meng R, Xiong Y, He J: Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation through interaction with EGFR and PTEN. Oncology reports 2015. doi: 10.​3892/​or.​2015.​4375.
43.
Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li H, Zhang Z: MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015
44.
Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546–52.CrossRefPubMed
45.
Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23:4014–22.CrossRefPubMedPubMedCentral
46.
Mori T, Martinez SR, O’Day SJ, Morton DL, Umetani N, Kitago M, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006;66:6692–8.CrossRefPubMedPubMedCentral
47.
Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23:9351–8.CrossRefPubMedPubMedCentral
48.
Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 2015;48:503–10.CrossRefPubMed
49.
Li Z, Yu X, Shen J, Liu Y, Chan MT, Wu WK. MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game. Cell Prolif. 2015;48:511–6.CrossRefPubMed
50.
51.
52.
Yu X, Li Z, Chen G, Wu WK. MicroRNA-10b induces vascular muscle cell proliferation through Akt pathway by targeting TIP30. Curr Vasc Pharmacol. 2015;13:679–86.CrossRefPubMed
53.
54.
Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48:278–83.CrossRefPubMed
55.
Li Z, Yu X, Shen J, Law PT, Chan MT, Wu WK. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 2015;6:13914–24.CrossRefPubMedPubMedCentral
56.
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One. 2013;8:e83080.CrossRefPubMedPubMedCentral
57.
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015;6:17559–69.CrossRefPubMedPubMedCentral
58.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.CrossRefPubMed
59.
Ludwig N, Nourkami-Tutdibi N, Backes C, Lenhof HP, Graf N, Keller A, et al. Circulating serum miRNAs as potential biomarkers for nephroblastoma. Pediatr Blood Cancer. 2015;62:1360–7.CrossRefPubMed
60.
Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Intl J Cancer J Intl Du Cancer. 2013;132:116–27.CrossRef
61.
Wei X, Chen D, Lv T, Li G, Qu S: Serum microRNA-125b as a potential biomarker for glioma diagnosis. Molecular neurobiology 2014
62.
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(Suppl):1241–6.CrossRefPubMedPubMedCentral
63.
Cleys ER, Halleran JL, McWhorter E, Hergenreder J, Enriquez VA, da Silveira JC, et al. Identification of microRNAs in exosomes isolated from serum and umbilical cord blood, as well as placentomes of gestational day 90 pregnant sheep. Mol Reprod Dev. 2014;81:983–93.CrossRefPubMed
64.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentral
65.
Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18:502–8.CrossRefPubMed
66.
Shiiyama R, Fukushima S, Jinnin M, Yamashita J, Miyashita A, Nakahara S, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23:366–72.CrossRefPubMed
67.
Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DS. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6:7053–64.CrossRefPubMedPubMedCentral
68.
Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61:187–93.CrossRefPubMed
69.
Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, et al. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMed. 2015;2:671–80.CrossRef
70.
Friedman EB, Shang S, de Miera EV, Fog JU, Teilum MW, Ma MW, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 2012;10:155.CrossRefPubMedPubMedCentral
71.
Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, Han SW, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121:51–9.CrossRefPubMed
72.
Tian R, Liu T, Qiao L, Gao M, Li J. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol. 2015;8:3097–103.PubMedPubMedCentral
Metadata
Title
Circulating epigenetic biomarkers in melanoma
Authors
Yu Xin
Zheng Li
Matthew T.V. Chan
William Ka Kei Wu
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4599-0

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells

Original Article

Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line

Original Article

Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma

Review

Determination of malignant potential of cervical intraepithelial neoplasia

Original Article

miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells

Original Article

miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits